Beyhan Durak Aras

BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.

The purpose of this study was to determine the frequency of BCL2, BCL6, IGH, TP53, and MYC protein expression and rearrangements of the respective genes in diffuse large B-cell lymphoma (DLBCL) patients and to assess their prognostic values. Samples from 44 patients with DLBCL were evaluated using fluorescence in situ hybridization and immunohistochemical analyses. BCL6 was the most rearranged gene (63.6%), followed by MYC (31.8%), TP53 (22.7%), and BCL2 (18.2%). Multiple rearrangements were detected in 40.9% of the cases. BCL6 was the most expressed protein (78.6%), followed by TP53 (69.04%), BCL2 (59.5%) and MYC (14.3%). Expression of multiple proteins was detected in 67.4% of the cases. BCL2 (P = .003) expression had a significant negative influence on overall survival,whereas BCL6 (P = .014) expression had a significant positive influence. Our results with a different pattern of gene rearrangements and associated protein overexpression indicate the molecular genetic complexity of DLBCLs, which reflects the morphologic, biologic, and clinical heterogeneity of these lymphomas.

IS THERE A RELATIONSHIP BETWEEN APOE GENOTYPES AND HOSPITALIZATION OF DEMENTIA PATIENTS

Background: To determine whether observed relationship between the genotype distribution of Apolipoprotein E and number and reason of hospitalisations amongs demented patients. Methods: We collected data on the basis of data from 630 dementia patients admitting to Eskisehir Osmangazi University dementia outpatient clinic who consented to the genotyped until present from 2000.Results: Themost common part of our patients was consisted of Alzheimer disease (41.9%). Remaining part were subsequently vascular dementia (33.3%), Frontotemporal dementia (7.6%), other group (tumors, hydrocephalus, endocrine vs. 5.6%), Mild cognitive impairment (4.4%), Lewy body dementia (3.3%), Corticobasal disorder (2.4%) and Progressive supranuclear palsy (1.4%). APOE genotype frequencies were 0.6 percent for E2/E2, 0.8 percent for E2/E4, 5.1 percent for E4/E4, 9 percent for E2/E3, 21.7 percent for E3/E4, 62.7 percent for E3/E3. While, In Alzheimer dementia was seen more often E3/3, 3/4, 4/4 than other dementia, the frequency E3/3, 2/3 and 3/4 were higher detected in vascular dementia, respectively. In frontotemporale dementia patients were no seen E4/4, 2/4 and 2/2 alleles. Vascular dementia patients admitted the most times to hospital than other dementia (<0.001). In contrast, Alzheimer patients developed the most complication during their disease (<0.05). These complications were respectively urinary tract (48%) or chest infections (36%), trauma (9%), the prerenal azotemia (4%) and deficiency of feeding (3%). Neither admitting to hospital nor complication type and number were no found differences in APOE genotypes. The used drugs like antidepressant or neuroleptics did not effect to depend on extraordinary events in demented patients. The differences between initial and last MiniMental Status Examination in all dementia patients did not observed the relationship the type of dementia and genotypes distribution of APOE. Conclusions: In conclusion, the APOE genotypes, especially APOE3/4 and 4/4, are not a significant predictor of number and reason of hospitalizations and complication except the natural progression of disease. It is not socio demographic data and can be accepted pathological data.